| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/28/2006 | US7018660 For therapy of seborrheic dermatitis, psoriasis, folliculitis, rosacea, perioral dermatitis, acne, or impetigo |
| 03/28/2006 | US7018656 Gel formulations of 1-hydroxy-2(H)pyridone derivatives, which contain solvents and hydrophilic gel-forming agents |
| 03/28/2006 | US7018647 Patches for external use |
| 03/28/2006 | US7018645 biodegradable and water soluble polyesterether block polymers used for drug delivery |
| 03/28/2006 | US7018631 Compositions and methods for sensitizing and inhibiting growth of human tumor cells |
| 03/28/2006 | US7018620 Delivery of beta-blockers through an inhalation route |
| 03/28/2006 | US7018609 For drug delivery |
| 03/28/2006 | US7017573 Methods and apparatus for relieving headaches, rhinitis and other common ailments |
| 03/28/2006 | CA2415750C Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 03/23/2006 | WO2006031922A2 Thyroid hormone analogs for promoting angiogenesis |
| 03/23/2006 | WO2006031467A2 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| 03/23/2006 | WO2006031337A2 Combinations of pkc activators and pkc inhibitors for alzheimer’s disease treatment and cognitive enhancement |
| 03/23/2006 | WO2006031312A2 Compositions and treatments using ex vivo activated cells for myelosuppressed patients |
| 03/23/2006 | WO2006030947A1 Joint use of sulfonamide based compound with angiogenesis inhibitor |
| 03/23/2006 | WO2006030941A1 Simultaneous use of sulfonamide-containing compound and angiogenesis inhibitor |
| 03/23/2006 | WO2006030925A1 Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| 03/23/2006 | WO2006030803A1 Purinenucleoside derivative modified in 8-position and medicinal use thereof |
| 03/23/2006 | WO2006030792A1 Pathologic model animal for non-alcoholic fatty hepatitis |
| 03/23/2006 | WO2006030761A1 Novel diabetes-associated factor |
| 03/23/2006 | WO2006030693A1 Agents for overcoming hair troubles and method of screening the same |
| 03/23/2006 | WO2006030306A2 Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder |
| 03/23/2006 | WO2006010634A8 Chn-1/chip-antagonists for the treatment of muscular diseases |
| 03/23/2006 | WO2005079284A3 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| 03/23/2006 | WO2005010025A3 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| 03/23/2006 | WO2004096254A3 Transferrin conjugates for tumor treatment |
| 03/23/2006 | WO2004019876A3 Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure |
| 03/23/2006 | US20060064068 body fluids, such as urine, feces, menses; comprises a skin conditioning agent, a viscosity enhancing agent and an oleophilic film-forming agent; applied to the skin by suitable delivery vehicles, such as absorbent articles or components thereof, sheet materials, pads, bandages, sponges, foam pads, pumps |
| 03/23/2006 | US20060063922 Epidermal differentiation factor |
| 03/23/2006 | US20060063840 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| 03/23/2006 | US20060063839 Inhibitors of decrease in body temperature |
| 03/23/2006 | US20060063835 Composition based on triethyl citrate for the treatment of bacterial infections of the skin |
| 03/23/2006 | US20060063813 Organic compounds |
| 03/23/2006 | US20060063810 Combination treatment for impaired motor function in parkinson's disease |
| 03/23/2006 | US20060063768 Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa |
| 03/23/2006 | US20060063758 Neuropeptide Y antagonist; antiarthritc agents; cardiovascular disorders; antidiabetic agents; kidney diseases; eating disorders; obesity |
| 03/23/2006 | US20060063753 Use of nefopam for the treatment of nausea or emesis |
| 03/23/2006 | US20060063748 Methods for treating psychosis associated with interferson-alpha therapy |
| 03/23/2006 | US20060063723 Pharmaceutical composition comprising esterol derivatives for use in cancer therapy |
| 03/23/2006 | US20060063235 DNA encoding the human serine protease C-E |
| 03/23/2006 | US20060062828 feeding animals such as cats and rabbits prone to hairball formation, with proteins, fats, dietary fibers and blends of beet pulp and carboxymethyl cellulose and salts |
| 03/23/2006 | US20060062789 Immunoglobulins; lupus, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, Hashimoto's disease, immunodeficiency syndrome, asthma, allergic disorders, AIDS, and proliferative disorders such as leukemia |
| 03/23/2006 | US20060062777 Inhibit tumor growth, or metastasis by modifying protein-protein interactions involving certain amino acid sequences within matrix metalloproteinase 9 (MMP-9) |
| 03/23/2006 | US20060062769 Using nestin-positive pancreatic stem cell to generate insulin producing beta cells; tissue engineering and repair; regenerative medicine |
| 03/23/2006 | DE10318714B4 Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches Drug combinations and therapies to combat alcohol abuse |
| 03/23/2006 | DE102004036907A1 Use of a 5-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor for the production of an agent to treat or prevent hyper plastic and/or dysplastic large intestine polyps |
| 03/23/2006 | CA2584528A1 Composition for inhibiting or preventing the formation of a biofilm |
| 03/23/2006 | CA2583410A1 Thyroid hormone analogs for promoting angiogenesis |
| 03/23/2006 | CA2580669A1 Pathologic model animal for nonalcoholic steatohepatitis |
| 03/23/2006 | CA2580370A1 Reducing er stress in the treatment of obesity and diabetes |
| 03/23/2006 | CA2580236A1 Purinenucleoside derivative modified in 8-position and medical use thereof |
| 03/23/2006 | CA2579501A1 Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| 03/23/2006 | CA2575788A1 Combination of pkc activators and pkc inhibitors for alzheimer's diseasetreatment and cognitive enhancement |
| 03/22/2006 | EP1637160A2 Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| 03/22/2006 | EP1637157A1 Pharmaceutical composition for the treatment of pelvic pain |
| 03/22/2006 | EP1637143A1 Sulfacetamide formulations further containing a sunscreen for treatment of rosacea |
| 03/22/2006 | EP1637141A1 Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease |
| 03/22/2006 | EP1637132A1 External preparation for athlete´s foot treatment |
| 03/22/2006 | EP1636585A2 Diaryl ureas with kinase inhibiting activity |
| 03/22/2006 | EP1636334A2 Recombinant anti-cd30 antibodies and uses thereof |
| 03/22/2006 | EP1635879A2 Lectin conjugates |
| 03/22/2006 | EP1635873A2 Chemical combination and method for increasing delivery of coenzyme q 10 |
| 03/22/2006 | EP1635850A1 Antimicrobial silver comprising silver |
| 03/22/2006 | EP1635847A1 Treatment of symptoms associated with bacterial vaginosis |
| 03/22/2006 | EP1635843A1 Therapy comprising dienogest for hormone replacement and depression |
| 03/22/2006 | EP1635842A1 Treatment of amd with combination of ingredients |
| 03/22/2006 | EP1635838A2 Prophylaxis and/or treatment of portal hypertension |
| 03/22/2006 | EP1635826A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 03/22/2006 | EP1635815A1 Methods and compounds for the treatment of vascular stenosis |
| 03/22/2006 | EP1635811A2 Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments |
| 03/22/2006 | EP1635807A1 Pharmaceutical combination comprising modafinil and another drug |
| 03/22/2006 | EP1635804A1 Use of iron for treating attention deficit hyperactivity disorder in children |
| 03/22/2006 | EP1635782A1 Tissue culture media used as a component of cosmetics |
| 03/22/2006 | EP1635766A2 Lactoferrin as an adjuvant in cancer vaccines |
| 03/22/2006 | EP1550460A4 Method for correcting immune responses and medicinal agent |
| 03/22/2006 | EP1412357B1 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 03/22/2006 | EP1411817A4 Method and apparatus for the photomodulation of living cells |
| 03/22/2006 | EP1404301A4 Stable controlled release pharmaceutical compositions containing pravastatin |
| 03/22/2006 | EP1377294B1 Use of neuroactive substances for the treatment of parkinsons disease and pharmaceutical combination |
| 03/22/2006 | EP1328253B1 Administration of a thiol-based chemoprotectant compound |
| 03/22/2006 | EP1322287B1 Microparticles for delivery of the heterologous nucleic acids |
| 03/22/2006 | EP1272488B1 Tri-aryl-substituted-ethane pde4 inhibitors |
| 03/22/2006 | EP1221963A4 Methods of inhibiting osteoclastogenesis |
| 03/22/2006 | EP1221847A4 Methods of enhancing chemotherapy |
| 03/22/2006 | EP1212089B1 Synergistic combination of roflumilast and salmeterol |
| 03/22/2006 | EP1129191B1 Methods of diagnosing or treating neurological diseases |
| 03/22/2006 | EP1051161B1 Method for treating alzheimer's disease |
| 03/22/2006 | EP1011695B1 Use of neurotoxin therapy for treatment of prostate disorders |
| 03/22/2006 | EP1005480B1 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
| 03/22/2006 | EP0946155B1 Pharmaceutical composition for treating fecal incontinence and anal itch |
| 03/22/2006 | EP0871440B1 Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists |
| 03/22/2006 | CN1751037A Sulfonamide derivatives as PPAR modulators |
| 03/22/2006 | CN1750839A Administration of capsaicinoids |
| 03/22/2006 | CN1750759A Method of treating functional bowel disorders |
| 03/22/2006 | CN1748794A Use of aza decyl meta pentalkenylone compounds |
| 03/22/2006 | CN1748672A Aseptic medicine composition |
| 03/22/2006 | CN1748653A Medicament distribution device |
| 03/22/2006 | CN1246311C Pyrrolidines which inhibit CAMP-specific PDE |
| 03/22/2006 | CN1245993C Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents |
| 03/22/2006 | CN1245988C Use of ATAZANAVIR in HIV therapy |
| 03/22/2006 | CN1245984C Preparation for prevention and/or treatment of vascular disorders |